TY - JOUR
T1 - Laryngeal mucous membrane pemphigoid serves as a prognostic factor for poor response to treatment with rituximab
AU - Baniel, A.
AU - Oestreicher-Kedem, Y.
AU - Peled, A.
AU - Bar-Ilan, E.
AU - Geller, S.
AU - Sprecher, E.
AU - Baum, S.
N1 - Publisher Copyright:
© 2021 British Association of Dermatologists
PY - 2021/7
Y1 - 2021/7
N2 - Mucous membrane pemphigoid (MMP) is an autoimmune blistering, scarring and occasionally mutilating disease that may progress to blindness or airway obstruction. Over the past few years, rituximab (RTX) has emerged as a potential therapeutic solution for MMP; however, the literature regarding its efficacy in the treatment of severe MMP is sparse. We studied four patients with recalcitrant MMP who were treated with RTX. Three of these had recalcitrant laryngeal disease; two were unresponsive to RTX, while the third patient achieved complete remission (CR) but relapsed twice. The fourth patient, who had oral and ocular disease, also achieved CR. In addition, we reviewed 143 cases of MMP treated with RTX reported in the literature to date. Of these, 120 had late observation endpoints, of whom 81 (67.5%) achieved CR, 24 (20%) received partial remission and 15 (12.5%) had no remission. Based on this study, the presence of laryngeal MMP seems to predict refractoriness to RTX treatment. In conclusion, we found that RTX can ameliorate the MMP course and that laryngeal involvement, which is known to be a prognostic factor for severe MMP, may also predict poor response to RTX.
AB - Mucous membrane pemphigoid (MMP) is an autoimmune blistering, scarring and occasionally mutilating disease that may progress to blindness or airway obstruction. Over the past few years, rituximab (RTX) has emerged as a potential therapeutic solution for MMP; however, the literature regarding its efficacy in the treatment of severe MMP is sparse. We studied four patients with recalcitrant MMP who were treated with RTX. Three of these had recalcitrant laryngeal disease; two were unresponsive to RTX, while the third patient achieved complete remission (CR) but relapsed twice. The fourth patient, who had oral and ocular disease, also achieved CR. In addition, we reviewed 143 cases of MMP treated with RTX reported in the literature to date. Of these, 120 had late observation endpoints, of whom 81 (67.5%) achieved CR, 24 (20%) received partial remission and 15 (12.5%) had no remission. Based on this study, the presence of laryngeal MMP seems to predict refractoriness to RTX treatment. In conclusion, we found that RTX can ameliorate the MMP course and that laryngeal involvement, which is known to be a prognostic factor for severe MMP, may also predict poor response to RTX.
UR - http://www.scopus.com/inward/record.url?scp=85106591973&partnerID=8YFLogxK
U2 - 10.1111/ced.14662
DO - 10.1111/ced.14662
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33811681
AN - SCOPUS:85106591973
SN - 0307-6938
VL - 46
SP - 915
EP - 919
JO - Clinical and Experimental Dermatology
JF - Clinical and Experimental Dermatology
IS - 5
ER -
